S1181 Treatment Satisfaction With Tenapanor (IBSRELA): Real-World Survey of Patients With Irritable Bowel Syndrome With Constipation

Introduction: Irritable bowel syndrome with constipation (IBS-C) is a common disorder of gut-brain interaction, characterized by abdominal pain, bloating, and constipation, that negatively impact patients’ quality of life (QoL). Tenapanor (TEN [IBSRELA]) is a sodium/hydrogen exchanger 3 inhibitor indicated for treatment of IBS-C in adults. Real-world data on TEN regarding treatment satisfaction, IBS-C symptom resolution, and improvement in QoL are lacking. Herein, we report results of a survey of patients receiving TEN for the treatment of IBS-C, which was conducted to address these data gaps. Methods: The survey was distributed via text messaging through the ArdelyxAssist patient assistance program (PAP). Patients were aged ≥18 years and actively receiving TEN—first dispensed ≥6.5 weeks prior and last dispensed within 90 days before the survey start. Multifactor ordered logistic regression analysis was performed to determine predictors of QoL improvements and treatment satisfaction. Results: Of the 4252 invites sent, 537 patients completed the survey. Most patients reported treatment satisfaction with TEN (88%) as well as improved constipation (95%), bloating (75%), and abdominal pain (84%). All 3 symptoms improved in 69% of patients. QoL also improved with TEN, with patients reporting that TEN improved their ability to participate in daily activities, including work (74%) or social activities and exercise (74%). Improvements in constipation, bloating, and abdominal pain were each predictive of improved QoL, while improvement in constipation was predictive of treatment satisfaction (OR, 3.19; P = 0.02). In response to open-ended questions about the impact of TEN, 87% of patients shared positive experiences with TEN, and 76% shared that TEN is better than other IBS-C medications they have used. Thirty percent of patients shared challenges, including side effects and partial symptom resolution with <3% mentioning that potential side effects impacted their QoL. Conclusion: Patients in the real world report treatment satisfaction and improvements in constipation, bloating, abdominal pain, and QoL with TEN. Patients expressed that TEN worked better and/or had fewer side effects than other medications. Overall, the findings highlight the effectiveness of TEN in the management of IBS-C.